{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:37:00Z","timestamp":1792417020712,"version":"4.4.0"},"reference-count":97,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy, with excellent survival but substantial variation in recurrence risk. Traditional clinicopathologic risk models, while still a cornerstone of current guidelines, overlook the biological differences between patients, resulting in both overtreatment and undertreatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Content<\/jats:title>\n                    <jats:p>\n                      Next-generation sequencing has advanced our molecular understanding of PTC by identifying recurrent driver mutations that shed light on tumor initiation. However, mutations fall short of explaining the full spectrum of clinical behavior. DNA-based mutation profiling offers a fixed snapshot of genetic alterations, while transcriptomics captures the tumor\u2019s active biological state, integrating signaling pathways, differentiation status, immune interactions, and metabolism. Large-scale efforts like The Cancer Genome Atlas, along with emerging transcriptomic classifiers, have shown that gene-expression subtypes (\u201cBRAF-like\u201d and \u201cRAS-like\u201d) more accurately predict iodine avidity, tumor aggressiveness, and treatment response than histology or genotype alone. Transcriptome-based tools such as Thyroid GuidePx\n                      <jats:sup>\u00ae<\/jats:sup>\n                      now allow for biologically informed risk stratification that goes beyond traditional clinicopathologic and mutation-only approaches.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary and outlook<\/jats:title>\n                    <jats:p>In the preoperative setting, transcriptomic testing can inform whether patients are best suited for active surveillance, lobectomy, or total thyroidectomy. Postoperatively, it sharpens decisions around completion surgery, radioactive iodine use, and the intensity of TSH suppression. Integrating transcriptomic data into clinical decision-making enables more precise selection for treatment escalation or de-escalation. To unlock the full potential of transcriptome-guided management in PTC, prospective validation and adoption into ATA and NCCN guidelines will be critical.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1737469","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T05:22:12Z","timestamp":1769577732000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Leveraging the transcriptome-phenotype relationship to guide clinical management of papillary thyroid cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Adrian","family":"Harvey","sequence":"first","affiliation":[{"name":"Department of Surgery, Cumming School of Medicine, University of Calgary","place":["Calgary, AB, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Walser","sequence":"additional","affiliation":[{"name":"Department of Surgery, Cumming School of Medicine, University of Calgary","place":["Calgary, AB, Canada"]},{"name":"Department of Surgery, Schulich School of Medicine & Dentistry, Western University","place":["London, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Lahamm-Andraos","sequence":"additional","affiliation":[{"name":"Department of Surgery, Cumming School of Medicine, University of Calgary","place":["Calgary, AB, Canada"]},{"name":"Department of Surgery, West Virginia University","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Yeo","sequence":"additional","affiliation":[{"name":"Department of Surgery, Cumming School of Medicine, University of Calgary","place":["Calgary, AB, Canada"]},{"name":"Department of Oncology, Cumming School of Medicine, University of Calgary","place":["Calgary, AB, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Wolfe","sequence":"additional","affiliation":[{"name":"Department of Surgery, Cumming School of Medicine, University of Calgary","place":["Calgary, AB, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Stretch","sequence":"additional","affiliation":[{"name":"Department of Surgery, Cumming School of Medicine, University of Calgary","place":["Calgary, AB, Canada"]},{"name":"Qualisure Diagnostics","place":["Calgary, AB, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Craig","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, University of Wollongong","place":["Wollongong, NSW, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver F.","family":"Bathe","sequence":"additional","affiliation":[{"name":"Department of Surgery, Cumming School of Medicine, University of Calgary","place":["Calgary, AB, Canada"]},{"name":"Department of Oncology, Cumming School of Medicine, University of Calgary","place":["Calgary, AB, Canada"]},{"name":"Qualisure Diagnostics","place":["Calgary, AB, Canada"]},{"name":"Arnie Charbonneau Cancer Institute, University of Calgary","place":["Calgary, AB, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0449","article-title":"All-cause and cause-specific mortality among low-risk differentiated thyroid cancer survivors in the United States","volume":"34","author":"Tran","year":"2024","journal-title":"Thyroid"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"B4","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American thyroid association management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2010.0178","article-title":"Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system","volume":"20","author":"Tuttle","year":"2010","journal-title":"Thyroid"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0466","article-title":"Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients","volume":"165","author":"Castagna","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/thy.2018.0462","article-title":"Active surveillance for T1bN0M0 papillary thyroid carcinoma","volume":"29","author":"Sakai","year":"2019","journal-title":"Thyroid"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-019-03021-y","article-title":"Active surveillance of low-risk papillary thyroid carcinoma: a promising strategy requiring additional evidence","volume":"145","author":"Ze","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-010-1137-6","article-title":"Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: a meta-analysis","volume":"17","author":"Zetoune","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/archoto.2009.163","article-title":"Prophylactic central neck dissection in stage N0 papillary thyroid carcinoma","volume":"135","author":"Zuniga","year":"2009","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"B11","article-title":"Role of prophylactic central neck dissection in cN0 papillary thyroid cancer","volume":"29","author":"Costa","year":"2009","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0272","article-title":"Real-world performance of the american thyroid association risk estimates in predicting 1-year differentiated thyroid cancer outcomes: A prospective multicenter study of 2000 patients","volume":"31","author":"Grani","year":"2021","journal-title":"Thyroid"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0252","article-title":"Practical performance of the 2015 american thyroid association guidelines for predicting tumor recurrence in patients with papillary thyroid cancer in South Korea","volume":"27","author":"Lee","year":"2017","journal-title":"Thyroid"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0055","article-title":"The prospective implementation of the 2015 ATA guidelines and modified ATA recurrence risk stratification system for treatment of differentiated thyroid cancer in a canadian tertiary care referral setting","volume":"32","author":"Wu","year":"2022","journal-title":"Thyroid"},{"key":"B15","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3390\/biomedicines11030911","article-title":"Application of the american thyroid association risk assessment in patients with differentiated thyroid carcinoma in a german population","volume":"11","author":"Eilsberger","year":"2023","journal-title":"Biomedicines"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2016.05.056","article-title":"Application of the new American Thyroid Association guidelines leads to a substantial rate of completion total thyroidectomy to enable adjuvant radioactive iodine","volume":"161","author":"Kluijfhout","year":"2017","journal-title":"Surgery"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2017.04.029","article-title":"Correct extent of thyroidectomy is poorly predicted preoperatively by the guidelines of the American Thyroid Association for low and intermediate risk thyroid cancers","volume":"163","author":"Dhir","year":"2018","journal-title":"Surgery"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13165","article-title":"The significance of unrecognized histological high-risk features on response to therapy in papillary thyroid carcinoma measuring 1\u20134 cm: implications for completion thyroidectomy following lobectomy","volume":"86","author":"Lang","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2019.04.036","article-title":"Lobectomy compared to total thyroidectomy for low-risk papillary thyroid cancer: A systematic review","volume":"242","author":"Vargas-Pinto","year":"2019","journal-title":"J Surg Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5280-6","article-title":"Lobectomy is a more Cost-Effective Option than Total Thyroidectomy for 1 to 4 cm Papillary Thyroid Carcinoma that do not Possess Clinically Recognizable High-Risk Features","volume":"23","author":"Lang","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/lary.28634","article-title":"Total thyroidectomy versus lobectomy in small nodules suspicious for papillary thyroid cancer: cost-effectiveness analysis","volume":"130","author":"Al-Qurayshi","year":"2020","journal-title":"Laryngoscope"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0045","article-title":"Progress in thyroid cancer genomics: A 40-year journey","volume":"33","author":"Fagin","year":"2023","journal-title":"Thyroid"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","year":"2014","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1501993","article-title":"Biologic and clinical perspectives on thyroid cancer","volume":"375","author":"Fagin","year":"2016","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206739","article-title":"BRAF mutations in papillary carcinomas of the thyroid","volume":"22","author":"Fukushima","year":"2003","journal-title":"Oncogene"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1220617","article-title":"A clinically useful and biologically informative genomic classifier for papillary thyroid cancer","volume":"14","author":"Craig","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-013-0029-5","article-title":"The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis","volume":"45","author":"Barbaro","year":"2014","journal-title":"Endocrine"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2690","article-title":"Association of TERT promoter mutation, but not BRAF mutation, with increased mortality in PTC","volume":"100","author":"George","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.417","article-title":"BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma","volume":"4","author":"Henke","year":"2015","journal-title":"Cancer Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29934","article-title":"Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients","volume":"122","author":"Song","year":"2016","journal-title":"Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.3288","article-title":"Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality","volume":"3","author":"Liu","year":"2017","journal-title":"JAMA Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3390\/cancers11091388","article-title":"BRAF inhibitors in thyroid cancer: clinical impact, mechanisms of resistance and future perspectives","volume":"11","author":"Crispo","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2023.04.007","article-title":"Molecular and cytogenetic features of NTRK fusions enriched in BRAF and RET double-negative papillary thyroid cancer","volume":"25","author":"Wu","year":"2023","journal-title":"J Mol Diagn"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0072","article-title":"RAS mutations in thyroid cancer","volume":"18","author":"Howell","year":"2013","journal-title":"Oncologist"},{"key":"B35","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41574-023-00920-6","article-title":"Genomic alterations in thyroid cancer: biological and clinical insights","volume":"20","author":"Landa","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-16-0003","article-title":"Understanding TERT promoter mutations: A common path to immortality","volume":"14","author":"Bell","year":"2016","journal-title":"Mol Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2022.1477","article-title":"Frequency of TERT promoter mutations in real-world analysis of 2,092 thyroid carcinoma patients","volume":"37","author":"Yang","year":"2022","journal-title":"Endocrinol Metab (Seoul)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2383","article-title":"Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease","volume":"98","author":"Landa","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-15-0533","article-title":"TERT promoter mutations in thyroid cancer","volume":"23","author":"Liu","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(90)90659-3","article-title":"PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas","volume":"60","author":"Grieco","year":"1990","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0318","article-title":"Gene fusions in thyroid cancer","volume":"28","author":"Yakushina","year":"2018","journal-title":"Thyroid"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2021.07.003","article-title":"Precision therapy for RET-altered cancers with RET inhibitors","volume":"7","author":"Thein","year":"2021","journal-title":"Trends Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"17588359221101691","DOI":"10.1177\/17588359221101691","article-title":"RET kinase inhibitors for RET-altered thyroid cancers","volume":"14","author":"Vodopivec","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"4116","DOI":"10.1038\/s41598-023-31055-3","article-title":"Systematic review of NTRK 1\/2\/3 fusion prevalence pan-cancer and across solid tumours","volume":"13","author":"O'Haire","year":"2023","journal-title":"Sci Rep"},{"key":"B45","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/cncr.28484","article-title":"ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer","volume":"120","author":"Leeman-Neill","year":"2014","journal-title":"Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ecl.2008.01.001","article-title":"Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia","volume":"37","author":"Paes","year":"2008","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B50","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1530\/ERC-16-0043","article-title":"Prevalence and phenotypic correlations of EIF1AX mutations in thyroid nodules","volume":"23","author":"Karunamurthy","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-19-0325","article-title":"Characterization of thyroid cancer driven by known and novel ALK fusions","volume":"26","author":"Panebianco","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/cncy.22694","article-title":"p53 expression in cytology samples may represent a marker of early-stage cancer","volume":"131","author":"Policardo","year":"2023","journal-title":"Cancer Cytopathol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40463-022-00594-6","article-title":"EIF1AX mutation in thyroid tumors: a retrospective analysis of cytology, histopathology and co-mutation profiles","volume":"51","author":"Elsherbini","year":"2022","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021907","article-title":"RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma","volume":"88","author":"Nikiforova","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200208000-00006","article-title":"PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses","volume":"26","author":"Nikiforova","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0067","article-title":"PAX8\/PPARgamma rearrangement in thyroid nodules predicts follicular-pattern carcinomas, in particular the encapsulated follicular variant of papillary carcinoma","volume":"24","author":"Armstrong","year":"2014","journal-title":"Thyroid"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1321937111","article-title":"Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer","volume":"111","author":"Kelly","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.959089","article-title":"Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases","volume":"13","author":"Huang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad697","article-title":"Characterizing genetic alterations related to radioiodine avidity in metastatic thyroid cancer","volume":"109","author":"Mu","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B60","doi-asserted-by":"publisher","first-page":"6058","DOI":"10.1038\/s41467-021-26343-3","article-title":"Single-cell transcriptomic analysis of the tumor ecosystems underlying initiation and progression of papillary thyroid carcinoma","volume":"12","author":"Pu","year":"2021","journal-title":"Nat Commun"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e1594","DOI":"10.1002\/ctm2.1594","article-title":"Spatial transcriptomics reveals prognosis-associated cellular heterogeneity in the papillary thyroid carcinoma microenvironment","volume":"14","author":"Yan","year":"2024","journal-title":"Clin Transl Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203208","article-title":"Preoperative diagnosis of benign thyroid nodules with indeterminate cytology","volume":"367","author":"Alexander","year":"2012","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0305","article-title":"Impact of the multi-gene thyroSeq next-generation sequencing assay on cancer diagnosis in thyroid nodules with atypia of undetermined significance\/follicular lesion of undetermined significance cytology","volume":"25","author":"Nikiforov","year":"2015","journal-title":"Thyroid"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0141","article-title":"The 2023 bethesda system for reporting thyroid cytopathology","volume":"33","author":"Ali","year":"2023","journal-title":"Thyroid"},{"key":"B65","doi-asserted-by":"publisher","first-page":"108882","DOI":"10.1016\/j.surg.2024.06.080","article-title":"Prognostication with Thyroid GuidePx in the context of tall cell variants","volume":"177","author":"Craig","year":"2025","journal-title":"Surgery"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02686","article-title":"Transcriptome analyses identify a metabolic gene signature indicative of dedifferentiation of papillary thyroid cancer","volume":"104","author":"Ma","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0502","article-title":"American thyroid association statement on surgical application of molecular profiling for thyroid nodules: current impact on perioperative decision making","volume":"25","author":"Ferris","year":"2015","journal-title":"Thyroid"},{"key":"B68","doi-asserted-by":"publisher","first-page":"101680","DOI":"10.1016\/j.beem.2022.101680","article-title":"Molecular testing in thyroid cancer diagnosis and management","volume":"37","author":"Sipos","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2023.1494","article-title":"Prognostic value of preoperative molecular testing and implications for initial surgical management in thyroid nodules harboring suspected (Bethesda V) or known (Bethesda VI) papillary thyroid cancer","volume":"149","author":"Schumm","year":"2023","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"B70","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3390\/cancers15020413","article-title":"Effect of having concurrent mutations on the degree of aggressiveness in patients with thyroid cancer positive for TERT promoter mutations","volume":"15","author":"Alohali","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B71","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3390\/cancers13040648","article-title":"TERT promoter mutations and the 8th edition TNM classification in predicting the survival of thyroid cancer patients","volume":"13","author":"Park","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0544","article-title":"RAS-mutated cytologically indeterminate thyroid nodules: prevalence of Malignancy and behavior under active surveillance","volume":"34","author":"Sfreddo","year":"2024","journal-title":"Thyroid"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1111\/pin.12737","article-title":"The new 4th edition World Health Organization classification for thyroid tumors, Asian perspectives","volume":"68","author":"Kakudo","year":"2018","journal-title":"Pathol Int"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.0386","article-title":"Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: A paradigm shift to reduce overtreatment of indolent tumors","volume":"2","author":"Nikiforov","year":"2016","journal-title":"JAMA Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqae043","article-title":"Diagnostic interobserver agreement for thyroid fine-needle aspirates: Effects of reviewer experience and molecular diagnostics","volume":"162","author":"Gokozan","year":"2024","journal-title":"Am J Clin Pathol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqx051","article-title":"Defining papillary carcinoma of the thyroid: A short review and analysis","volume":"148","author":"Vollmer","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2004.08.010","article-title":"Surgical pathological second opinion in thyroid Malignancy: impact on patients' management and prognosis","volume":"31","author":"Hamady","year":"2005","journal-title":"Eur J Surg Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200211000-00014","article-title":"Observer variation of encapsulated follicular lesions of the thyroid gland","volume":"26","author":"Hirokawa","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0052","article-title":"Prognostic value of vascular invasion in well-differentiated papillary thyroid carcinoma","volume":"25","author":"Wreesmann","year":"2015","journal-title":"Thyroid"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/ans.16202","article-title":"Lymphovascular invasion and risk of recurrence in papillary thyroid carcinoma","volume":"90","author":"Wagner","year":"2020","journal-title":"ANZ J Surg"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-023-09788-8","article-title":"A critical assessment of diagnostic criteria for the tall cell subtype of papillary thyroid carcinoma-how much? How tall? And when is it relevant","volume":"34","author":"Turchini","year":"2023","journal-title":"Endocr Pathol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab388","article-title":"Tall cell percentage alone in PTC without aggressive features should not guide patients' clinical management","volume":"106","author":"Poma","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14316","article-title":"The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta-analysis","volume":"94","author":"Chen","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0350","article-title":"Effects of coexistent BRAF(V600E) and TERT promoter mutations on poor clinical outcomes in papillary thyroid cancer: A meta-analysis","volume":"27","author":"Moon","year":"2017","journal-title":"Thyroid"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13413","article-title":"Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis","volume":"87","author":"Vuong","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-13089-5","article-title":"Selection criteria for completion thyroidectomy in follicular thyroid carcinoma using primary tumor size and TERT promoter mutational status","volume":"30","author":"Park","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s13139-018-0522-0","article-title":"Factors associated with dose determination of radioactive iodine therapy for differentiated thyroid cancer","volume":"52","author":"Hong","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"key":"B88","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.3390\/cancers16173096","article-title":"Decision variables for the use of radioactive iodine in patients with thyroid cancer at intermediate risk of recurrence","volume":"16","author":"Newman","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.180240","article-title":"TERT promoter mutation predicts radioiodine-refractory character in distant metastatic differentiated thyroid cancer","volume":"58","author":"Yang","year":"2017","journal-title":"J Nucl Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1002\/iub.2056","article-title":"TERT promoter mutation in primary papillary thyroid carcinoma lesions predicts absent or lower (131) i uptake in metastases","volume":"71","author":"Meng","year":"2019","journal-title":"IUBMB Life"},{"key":"B91","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.3390\/cancers13092048","article-title":"Genetic determinants for prediction of outcome of patients with papillary thyroid carcinoma","volume":"13","author":"Povoa","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0542","article-title":"Clinical application of next-generation sequencing in advanced thyroid cancers","volume":"32","author":"Ma","year":"2022","journal-title":"Thyroid"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/hed.27025","article-title":"American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment","volume":"44","author":"Shonka","year":"2022","journal-title":"Head Neck"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02767","article-title":"Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion","volume":"40","author":"Chakravarty","year":"2022","journal-title":"J Clin Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0033","article-title":"NCCN guidelines(R) insights: thyroid carcinoma, version 1.2025","volume":"23","author":"Haddad","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B96","doi-asserted-by":"publisher","first-page":"2200024","DOI":"10.1002\/ggn2.202200024","article-title":"Transcriptomics for clinical and experimental biology research: hang on a seq","volume":"4","author":"Stokes","year":"2023","journal-title":"Adv Genet (Hoboken)"},{"key":"B97","doi-asserted-by":"publisher","first-page":"5978","DOI":"10.3390\/molecules29245978","article-title":"RNA stability: A review of the role of structural features and environmental conditions","volume":"29","author":"Kornienko","year":"2024","journal-title":"Molecules"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1737469\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:13:52Z","timestamp":1771924432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1737469\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":97,"alternative-id":["10.3389\/fendo.2026.1737469"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1737469","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"article-number":"1737469"}}